Definium Therapeutics
DFTX· Manufacturing· Fiscal year ends in December
CEO pay in FY2024Stock +90.2% in FY2024
Robert Barrow is the CEO of Definium Therapeutics and was paid $2.7M in FY2024 (Dec), up 25%.
Pay$100 in the stock at the end of FY21 → $34
Executives3
See all- 1Brandi L. RobertsChief Financial OfficerFY2025
- 2Daniel Karlin, M.D.Chief Medical OfficerFY2025
- 3Robert BarrowChief Executive OfficerFY2024
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allDefinium Therapeutics paid its 2 named executives $9.1M in total in FY2025 (Dec).
| Name | |||
|---|---|---|---|
| Brandi L. RobertsChief Financial Officer | Not disclosed | Not disclosed | |
| Daniel Karlin, M.D.Chief Medical Officer | |||
| Robert BarrowChief Executive Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers19
See allThe comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board5
See all- Carol A. ValloneChair · 4 yr on the boardIndependentAudit, Compensation—Paid as an executive
- Andreas KrebsDirector · 4 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive
- Robert BarrowDirector · 4 yr on the boardNot independent—Paid as an executive
- Suzanne Bruhn, Ph.D.Director · 3 yr on the boardIndependentCompensation (Chair), Nominating and Corporate Governance—Paid as an executive
- Roger AdsettDirector · -1 yr on the boardIndependent—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 27, 2026 | FY2025 |
| Annual report | 10-K | Feb 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 23, 2025 | FY2024 |
| Annual report | 10-K | Mar 6, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Feb 28, 2024 | FY2023 |
